Primary cerebral low-grade B-cell lymphoma, monoclonal immunoglobulin deposition disease, cerebral light chain deposition disease and “aggregoma”: an update on classification and diagnosis

Skardelly et al.
Primary cerebral low-grade B-cell lymphoma, monoclonal immunoglobulin deposition disease, cerebral light chain deposition disease and “aggregoma”: an update on classification and diagnosis

Marco Skardelly*, Georgios Pantazis, Sotirios Bisdas, Guenther C Feigl, Martin U Schuhmann, Marcos S Tatagiba and Rainer Ritz

Abstract

Background: This work aims to add evidence and provide an update on the classification and diagnosis of monoclonal immunoglobulin deposition disease (MIDD) and primary central nervous system low-grade lymphomas. MIDD is characterized by the deposition of light and heavy chain proteins. Depending on the spatial arrangement of the secreted proteins, light chain-derived amyloidosis (AL) can be distinguished from non-amyloid light chain deposition disease (LCDD). We present a case of an extremely rare tumoral presentation of LCDD (aggregoma) and review the 3 previously published LCDD cases and discuss their presentation with respect to AL.

Case presentation: A 61-year-old woman presented with a 3½-year history of neurologic symptoms due to a progressive white matter lesion of the left subcortical parieto-insular lobe and basal ganglia. 2 former stereotactic biopsies conducted at different hospitals revealed no evidence of malignancy or inflammation; thus, no therapy had been initiated. After performing physiological and functional magnetic resonance imaging (MRI), the tumor was removed under intraoperative monitoring at our department. Histological analysis revealed large amorphous deposits and small islands of lymphoid cells.

Conclusion: LCDD is a very rare and obscure manifestation of primary central nervous system low-grade lymphomas that can be easily misdiagnosed by stereotactic biopsy sampling. If stereotactic biopsy does not reveal a definite result, a “wait-and-see” strategy can delay possible therapy for this disease. The impact of surgical removal, radiotherapy and chemotherapy in LCDD obviously remains controversial because of the low number of relevant cases.

Keywords: Aggregoma, Light chain deposition disease, Lymphoma, Monoclonal immunoglobulin deposition disease, Neurooncology, Primary central nervous system lymphoma, Stereotaxic surgery
Background

Primary central nervous system lymphomas (PCNSL) are defined as non-Hodgkin’s (NHL) lymphomas that primarily arise in the central nervous system [1]. PCNSL account for approximately 1–2% of all primary cerebral tumors, and approximately 98–99% are classified as diffuse B-cell lymphoma (analogous to systemic B-cell NHL) [2,3]. Intracerebral manifestations of T-cell lymphomas and secondary lymphomas are extremely rare [3]. Low-grade PCNSL represents a less aggressive subgroup compared with systemic NHL and accounts for approximately 3–20% of all PCNSL [4,5]. Only a few low-grade PCNSL are associated with the deposition of monoclonal light and heavy chain immunoglobulins (Ig).

Monoclonal immunoglobulin deposition disease (MIDD) is characterized by the deposition of monocytic light and/or heavy chain proteins in various tissues and organs. MIDD mainly affects the kidneys, but the involvement of other organs (e.g., the liver, heart and peripheral nerves) is not uncommon [6]. All forms of MIDD can be ascribed to monoclonal expansion of an immunoglobulin (Ig) light and/or heavy chain producing B-cells [7]. 2 subgroups of MIDD can be differentiated histologically based on the different spatial arrangement of the secreted proteins. In the more common subgroup, the light chain-derived amyloidosis (AL) subgroup, proteins are aggregated in fibrils to β-pleated sheets that stain for Congo red and display green birefringence under polarized light [8]. The second subgroup is characterized by ultrastructural non-organized proteins, which aggregate in more amorphous Congo red-negative deposits. Randall and colleagues initially described 2 patients with the systemic deposition of non-amyloid Ig light chains and proposed the term light chain deposition disease (LCDD) [9]. Subsequent reports confirmed the existence of systemic heavy chain deposition disease (HCDD) as well as both light and heavy chain deposition disease (LHCDD) [10].

We provide an update regarding the diagnosis and classification of primary cerebral low-grade B-cell lymphomas and cerebral light chain deposit diseases. We present the case of a patient with a 3½-year progressive hemiparesis and hemi-hypoesthesia of the right side due to a delayed diagnosis and therapy of the extremely rare, tumor-presenting cerebral restricted LCDD, which can be called “aggregoma” [11]. We further present a systematic overview and discussion of the disease with respect to light chain-derived amyloidosis.

Case presentation

Clinical presentation

A 61-year-old woman was admitted to our department with progressive brachiofacially accentuated hemiparesis, dysdiadochokinesia and hemi-hypoesthesia of the right side of the body, which began 3½ years previous. She initially presented with dyspraxia and fluctuating hypoesthesia of the right hand at the end of 2006; her cranial nerves were not affected. She complained of increased fatigue but did not present with weight loss, night sweats, fever or headache. The woman had a history of hypothyroidism related to Hashimoto’s thyroiditis and suffered endocarditis and streptococcal sepsis in 1982. She was under a long-term medication treatment of 100 μg of thyroxin daily. An MRI scan performed in May 2007 revealed a 2.8 × 2.0 × 2.4 cm lesion of the white matter at the level of the left subcortical parieto-insular lobe and basal ganglia (Figure 1a). The lesion presented as hypointense on T1-weighted scans with some regions displaying slight enhancement after gadolinium administration and moderate inhomogeneous hyperintensity on T2-weighted scans. Blood serum inflammatory markers (leukocytes and CRP), cerebrospinal fluid protein, and the cell count revealed no abnormalities. A stereotactic serial biopsy was performed in June 2007. The histological analysis demonstrated colloidal-bodied particles with scattered single cells with no proof of tumors or inflammatory cells. Based on the obvious diagnosis of an atypical colloidal cyst, no further therapy was initiated. The first control MRI (3 months after biopsy) demonstrated no progression of the disease. However, a clinical deterioration and progression of the lesion (3.6 × 2.3 × 2.6 cm) (Figure 1b & 1c) at the follow-up MRI session in July 2008 warranted a stereotactic serial biopsy, which was conducted at a neurosurgical clinic that specialized in stereotactic procedures. Prior to the stereotactic surgery, CSI (chemical shift imaging) was performed, which revealed a prominently reduced NAA peak, an elevation of lactate and only slight alterations of choline and creatine peaks (Figure 1d & 1e).

The histological analysis of the biopsy that was performed in June 2007 showed a glial cyst but exhibited no evidence of malignancy or inflammation. In May 2010, the patient presented for the first time at our department because of clinical and radiological progression of the disease. Surgical resection of the lesion with a subsequent histological diagnosis was recommended. At the day of admission, the patient displayed poorer health and a worsened nutritional status. The neurological examination demonstrated moderate hemiparesis of the right side and hemi-hypoesthesia, including the trigeminal nerve, with no other cranial nerve deficits. The woman had a high-grade disturbance of the fine motor skills of the right hand, dysdiadochokinesia of the right side and displayed an unstable standing posture and gait. Her reflexes exhibited increased positive Troemner’s and Babinski’s signs. On the day of admission, a control MRI that included diffusion tensor imaging and a functional MRI were performed. The lesion progressed in volume to 4.2 × 3.2 × 5.3 cm (Figure 2a) with the same signal characteristics in T1- and T2-weighted imaging; displacement of the left pyramidal...
Figure 1 MRI and MR spectroscopy of the tumor. (a) Axial T2-weighted image shows a sharply demarcated, hyperintense lesion on the posterior aspect of the left basal ganglia and the subcortical left parieto-insular lobe. The lesion affects the internal and external capsules without reaching the insular cortex. (b) Follow-up MR imaging after 1 year demonstrates progression of the lesion size, particularly on the posterior part, with medially located hyperintense foci corresponding to microcysts on T2-weighted imaging. (c) Coronal T1-weighted MR imaging after gadolinium administration shows punctual enhancement within the lesion. (d) Proton MR spectroscopy using a short echo time (TE: 30 ms) on the lateral part of the lesion reveals a reduced NAA peak and reduced lactate levels (1.3 ppm). The lactate concentration appears more prominent on the medial part of the lesion (and correlates with the microcystic, necrotic changes observed in Figure 1b), as shown on the metabolic map overlaid on the axial T2-weighted image (e).
and corticopontine tract was observed (Figure 2b) with significantly altered values of the fractional anisotropy compared with the healthy contralateral side.

**Intervention and postoperative course**

The patient underwent a left-sided standard pterional craniotomy and a removal of the lesion via a transsylvian, transinsular approach (with respect to the displacement of the left pyramidal and corticopontine tracts) under continuous intraoperative monitoring with sensory evoked and motor evoked potentials (SEPs and MEPs, respectively). The lesion appeared intraoperatively as an amorphous, gelatinous mass with some regions appearing dull and lucid (Figure 3). The tumor mass could be almost completely removed with the preservation of the MEPs and SEPs. After the operation, the patient exhibited increased hemiparesis of the right side with hemiplegia of the right arm and partial facial palsy in addition to a new expressive aphasia. A postoperative head CT revealed no signs of bleeding or infarction. By the time of discharge, the patient had partially recovered from aphasia and was mobilized with a Zimmer frame. In the follow-up control in the outpatients’ department after rehabilitation in October 2010, the patient demonstrated almost complete recovery from expressive aphasia and had slight palsy of the marginal mandibular branch of the facial nerve but continued to display moderate brachially accentuated hemiparesis of the right side. Subsequently, the department of hematooncology initiated diagnostic staging, and no further manifestations of B-cell lymphoma could be identified. Whole-body CT, abdominal ultrasound and bone marrow puncture revealed no suspicious findings. Electrophoresis showed a regular distribution and quantity of serum proteins (7.6 g/dl) and immunoglobulins. Additionally, there was no hint of monoclonality of serum proteins in the immunofixation assay. Physiological albuminuria in urine electrophoresis was observed.

**Neuropathology**

Histological examination of the resected tumor revealed large, amorphous, proteinaceous eosinophilic deposits and small islands of lymphoid cells between them (Figure 4a). The amorphous deposits were strongly PAS positive but negative for Congo red staining and did not display apple-green birefringence under polarization (Figure 4b). Most of the small lymphoid cells expressed the B-cell marker CD20 (Figure 4c). There were also few CD3-positive T-cell lymphocytes (Figure 4d). Immunoreactivities for the Ig-A heavy chain (Figure 4e) and λ-light chain immunoglobulins (Figure 4f) were partially observed in the deposits, plasmacytoid lymphocytes and mature plasma cells. The plasmacytic cells expressed CD38 and CD138, whereas they were negative for C79a. There was a negative reaction for IgM, IgG and IgE heavy chains.
and for \( \kappa \)-light chains. The lymphoid cells had a low proliferation rate (IHC for Ki67, 3 %). Some expressed bcl2, a few lymphocytes expressed CD5, and there was negative immunoreactivity for CD10, CD19, MUM1 and bcl6. Semi-nested PCR revealed monoclonal amplification of the complementarity-determining region III (CDR III) of the immunoglobulin heavy chain gene [1], supporting the diagnosis of low-grade lymphoplasmacytic lymphoma with light chain deposition disease and IgA- and \( \lambda \)-light chain restriction.

**Discussion**

Insoluble amyloid- or light chain-related non-amyloid aggregates can be formed by systemically secreted proteins, mainly involving the kidneys or occurring in an organ-specific manner [12]. Different CNS diseases are associated with amyloid depositions in the brain (e.g., Alzheimer’s disease, cerebral amyloid angiopathy, prion-related diseases or light chain-derived amyloidosis (AL)) [13]. The organ-specific, space-occupying solitary tumoral presentation of AL is called *amyloidoma*; regarding LCDD, the corresponding term *aggregoma* was suggested by Rostagno et al. in 2002. He first reported 3 patients who had tumoral masses of non-amyloid \( \kappa \)-light chain aggregates: 2 with cervical masses and 1 with a solitary lung nodule [11]. To date, 50 cases of cerebral-restricted AL have been reported [14-16]. In addition to 30 intracerebral solitary amyloidomas that mainly exhibited \( \lambda \)-type amyloids (but in some cases both \( \lambda \)- and \( \kappa \)-type amyloids), 20 further cases that exclusively demonstrated \( \lambda \)-type amyloids were published [14,16]. The latter included 8 cases of restricted AL with intracranial plasmocytes; 2 cases with PCNSL;
1 case with leptomeningeal amyloid angiopathy; 6 cases with multiple sclerosis; and 3 cases with widespread subcortical vascular amyloidosis with leukoencephalopathy (WSVAL). For further details, see the review by Schröder and colleagues [15]. By contrast, excluding our case, only 3 intracerebral LCDD cases were previously reported: 2 diffuse manifestations of λ-light chain aggregates [17,18] and 1 case of vascular presentation of non-amyloid λ-light chain aggregates, designated as cerebral LCDD vasculopathy (CLCDDV) [19]. For details about these cases see “Additional file 1”.

The case presented here is the first report on tumoral presentation of a brain-restricted LCDD that can be called an aggregoma. To create a better understanding of the relationships of the involved diseases they were classified in a pedigree (Figure 5); an overview of the details of the different manifestations of MIDD, AL and LCDD is provided in Table 1.

In systemic amyloidosis or LCDD, the CNS is usually not affected because of the blood–brain-barrier (BBB), which protects the brain sufficiently from circulating harmful metabolites (e.g., misfolded proteins) [20]. Nevertheless, 54 cases of either brain-restricted amyloid or non-amyloid deposition diseases, including our case, have been reported thus far (Table 1). Most of the depositions were located in the subcortical periventricular white matter, a preferred location for B-cell lymphoma [5]. Plasma cells were associated with deposits in many of the published cases with proof of monoclonality in some cases, suggesting isolated intracerebral production of monoclonal immunoglobulins by monoclonal B-cell lymphocytes [15,19,21]. It appears that the BBB exerts its function of controlling the exchange of metabolites in both directions because in none of the 54 cases were other organ systems involved. In both isolated cerebral LCDD and AL, it has been shown that brain deposits mainly consist of λ-type light chains that form either amyloid or non-amyloid aggregations. Only in 5 cases of ICA were both κ- and λ-type amyloids demonstrated [16-19]. It is not clear why the same proteins demonstrate different behaviors of aggregation; however, there is evidence that both the micro-environmental conditions and intrinsic amino acid sequence determine protein aggregation behavior [18]. To date, all 3 published aggregoma studies revealed κ-light chains, exclusively [11]. Hence, under micro-environmental conditions that are not associated with the formation of amyloids, tumoral aggregation of light chains could be restricted to the sequence of κ-light chain amino acids. However, we provide evidence of a tumoral formation of λ-light chain deposits, which confounds this notion.

As in other neurological diseases, the clinical presentation of MIDD depends mainly on the location of protein deposition and not on the histological finding. The major clinical signs of LCDD in the brain are epileptic seizures, cognitive impairments, headaches, and in the case presented here, hemiparesis, all of which were the main neurological symptoms observed in intracerebral amyloidoma (Table 1; for details, see Additional file 1). Cerebral imaging techniques such as CT and MRI are rarely specific for the diagnosis of the underlying histopathology. In the case presented here, we observed a tumor mass that was hypointense in T1-weighted scans and isointense to hyperintense in T2-weighted scans with

**Figure 5 Schematic of classification of the disease.** Pathological presentation of both entities of monoclonal immunoglobulin deposition diseases (MIDD), light chain-derived amyloidosis (AL) and light chain deposition disease (LCDD) in relation to the underlying disorders. The assignment of the reported case within the pedigree is highlighted in bold letters and lines. CAA = Cerebral amyloid angiopathy; CLCDDV = Cerebral LCDD vasculopathy; PCNSL = Primary central nervous system lymphoma; ICA = Intracerebral amyloidoma, WSVAL = Widespread subcortical vascular amyloidosis with leukoencephalopathy.
Table 1 Summary of findings of intracerebral light chain deposition diseases (No. 1–4) in comparison to intracerebral amyloidomas (No.5)

| No. and Source | 1 | 2 | 3 | 4 | 5* |
|----------------|---|---|---|---|----|
| Fischer et al. [18] 2006 | 19 | 35 | 72 | 61 | 49 (15–71) |
| Popovic et al. [19] 2007 | M | M | M | F | 13F, 17M |
| Pantazis et al. [17] 2010 | Generalized epileptic seizure | Focal epileptic seizure (hemiparesis) | Hemiparesis | Epileptic seizures (12) |
| Present case | Hemiparesis | Gait disturbance (2) |
| Foreid et al. [16] 2010 | 13F, 17M |
| Fischer et al. [14] 2007 - (1935–2010) - | 13F, 17M |
| Age | 19 | 35 | 72 | 61 | 49 (15–71) |
| Sex | M | M | M | F | 13F, 17M |
| Initial clinical presentation | Generalized epileptic seizure | Focal epileptic seizure (hemiparesis) | Hemiparesis | Epileptic seizures (12) |
| | A) Progressive bulbar palsy | B) Putative paranoid schizophrenia | Hemiparesis | Gait disturbance (2) |
| | | | Visual impairment (4) |
| | | | Cognitive impairment (5) |
| | | | Hearing loss (1) |
| Duration of symptoms | No | A) 1 ½ years | 8 years | 3 ½ years | NA |
| | B) 13 years | | | | |
| First location | Subcortical | Subcortical | Subcortical | Subcortical (21) |
| | periventricular posterior horn | periventricular gyrus rectus & periventricular parietal lobe | parieto-insular lobe & basal ganglia | Subcortical & cortical (8) |
| Diagnostic | Stereotactic Biopsy | Autopsy | Stereotactic Biopsy | Resection |
| | | | | |
| CT and MRI-Findings | T2: Diffuse hyperintense mass with perifocal edema | NA in detail | T1 + GL: Not enhanced T1-Hypointense T1+GL: Enhanced | CT: Hypodense CT+CM: Enhanced |
| | | | T1: Hypointense T2: Hyperintense | T1: Hypointense |
| | | | T2: Iso- to hyperintense T2: Iso- to hyperintense |
| Histomorphology | - Light chain deposits within vessel wall - B cell lymphoma with plasma-cellular different | - Light chain deposits - B cell lymphoma with abundant plasma cells | - Light chain deposits - Diffuse lymphoplasmacytic B-cell lymphoma | - Light chain deposits - Amyloid deposits - around blood vessels |
| | - Infiltrating T-cells - Monoclonal B-cell proliferation - Infiltrating T-cells | - Infiltrating T-cells - Infiltrating T-cells | - Infiltrating T-cells Infiltrating T-cells | - within vessel wall - within vessel wall - within vessel wall |
| | - Plasmacytic B-cell proliferation | - Infiltrating T-cells | - Infiltrating T-cells | - Infiltrating T-cells |
| Immunohistochemistry | - Congo red neg. - λ-Light chain deposits | - Congo red neg. - λ-Light chain deposits | - Congo red neg. - λ-Light chain deposits and IgA | - Congo red positive - λ-Light chain deposits |
| | - Plasmacytic B-cell proliferation | - Plasmacytic B-cell proliferation | - 7–12-nm fibrils |
| | - Ki67: 2% - Ki67: 3% | - Ki67: 2% - Ki67: 3% | - 7–12-nm fibrils |
| | - CD3+, CD5+, CD20+, CD23, Cyclin D' | - CD3+, CD5+, CD20+, CD10, CD79a, CD138 | - CD20+, CD5+, CD3+ |
| | - CD3+, CD5+, CD20+, CD23, Cyclin D' | - CD3+, CD5+, CD20+, CD10, CD79a, CD138 | - 14/16 | - k-light chain + 2/16 |

* N = X/30, number of patients with the presented characteristics of all presented cases of all N=30 intracerebral amyloidomas.
a slight enhancement after an application of gadolinium. These MRI characteristics are also usually observed in ICA (Table 1; for details, see Additional file 1). Other published cases of brain-isolated LCDD showed similar MRI properties but a more diffuse protein deposition similar to other brain diseases such as low-grade astrocytomas, cerebral lymphomas and inflammatory diseases of the white matter.

Because both, the clinical presentation and imaging features of various cerebral disorders are not specific, histological analysis functions as a pivot point for further therapeutic strategy. Depending on the location of the disease, the distinction of adjacent healthy brain tissue and the involvement of eloquent areas, a straightforward surgical removal, or an open alternative stereotactical biopsy would be the methods of choice. For ICA, it is known that medical treatment is not successful, but surgical removal has a good prognosis if the tumor can be removed completely [22,23]. For cerebral-restricted LCDD, only data from the therapy of 2 cases are available thus far and only for a time period of 24 months at the longest. Fischer et al. reported that after 3 cycles of methotrexate, the disease was steady for at least 24 months after the onset of symptoms and even a slight decrease in lesion size was observed by MRI after 6 months (for details, see Additional file 1, Case I). Although Pantazis and colleagues also demonstrated stability of the disease by 20 months after chemotherapy with Rituximab (MabThera™, Rituxan™), Trofosfamide (Ixoten™) and steroids, the control MRI new lesions after 16 months (for details, see Additional file 1, Case III). The data suggest that chemotherapy can provide at least a temporary benefit for disease progression but is most likely not sufficient to cure the disease possibly because of the drugs that cannot enter the brain across the intact BBB in sufficient levels to exert their full effect. One would assume an even weaker effect on *aggregonemas* because penetration of the drugs across the BBB into the space-occupying lesion is strongly impaired, as it was also demonstrated for ICA [22].

**Conclusion**

MIDD is a very rare and obscure manifestation of primary central nervous system low-grade lymphoma. The disease is characterized by monoclonal production of immunoglobulins that can occur in an isolated manner in the brain due to the BBB. The case on tumoral aggregation of light chain deposits presented here, confounds the former assumption that tumoral aggregation of light chains is restricted to κ-light chain amino acids. To date, only 53 cases of MIDD have been published, including 50 cases of cerebral-restricted light chain-derived amyloidosis and 3 cases of the even less frequent non-amyloid light chain deposition disease. In the case presented here, the lesion was located in an eloquent area of the brain, which necessitated 2 stereotactic biopsies, both of which were performed at other hospitals (one in June 2007 and the other in July 2008) and demonstrated no evidence of malignancy or inflammation. However, the patient showed continuous tumor progression and clinical deterioration. After resection, histopathological examination determined that most of the tumor consisted of large, amorphous, proteinaceous, eosinophilic deposits with small islands of lymphoid cells between the deposits. The lack of awareness of LCDD and its unique histological presentation contribute to the risk of misdiagnosis and underscore the need for a careful description of this disease and the limitations of biopsy. To date, the best therapeutic strategy for this disease remains controversial because the impact of surgical removal, radiotherapy and chemotherapy cannot be reliably evaluated due to the low number of cases thus far.

**Consent**

“Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Series Editor of this journal”.

**Additional file**

Additional file 1: LCDD - case summary.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

MS composed the abstract, introduction and discussion, as well as the conclusion of the manuscript and created the illustration of the involved diseases. GP did the histological analysis, created the histological figures and wrote the histological section. SB created the MRI figures, did the MRI image analysis and wrote the MRI section. GF treated the patient on the ward, helped with the draft of the clinical case and performed the literature search. MS performed the surgical intervention, prepared the intraoperative picture and wrote the surgical section. MT did the surgical intervention, initiated the draft of the case report and helped with the design of the manuscript. RR participated in the design of the case report and coordinated and substantially helped with the draft of the key manuscript sections. All authors read and approved the final manuscript.

**Acknowledgement**

We acknowledge support by Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of Tuebingen University.

**Author details**

1Department of Neurosurgery, University Hospital Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Baden-Wuerttemberg, Germany.
2Institute of Brain Research, University Hospital Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Baden-Wuerttemberg, Germany.
3Department of Neuroradiology, University Hospital Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Baden-Wuerttemberg, Germany.

Received: 21 September 2012 Accepted: 6 August 2013
Published: 15 August 2013
References

1. Plasswilm L, Herrlinger U, Korfel A, Weller M, Küker W, Kanz L, Thiel E, Barnberg M: Primary central nervous system (CNS) lymphoma in immunocompetent patients. Ann Hematol 2002, 81:415–423.

2. Jellinger KA, Paulus W: Primary central nervous system lymphomas–new pathological developments. J Neurol 1993, 240:25–36.

3. Reiche W, Hagen T, Schuchardt V, Billmann P: Diffusion-weighted MR imaging improves diagnosis of CNS lymphomas: A report of four cases with common and uncommon imaging features. Clin Neurol Neurosurg 2007, 109:92–101.

4. Paulus W: Classification, pathogenesis and molecular pathology of primary CNS lymphomas. J Neuro Oncol 1999, 43:203–208.

5. Jahnke K, Thiel E, Schilling A, Herrlinger U, Weller M, Coupland SE, Krümpelmann U, Stein H, Korfel A: Low-grade primary central nervous system lymphoma in immunocompetent patients. Br J Haematol 2005, 128:616–624.

6. Pozzi C, Fogazzi GB, Banfi G, Strom EH, Ponticelli C, Locatelli F: Renal disease and patient survival in light chain deposition disease. Clin Nephrol 1995, 43:281–287.

7. Buixa JM: Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematol Oncol Clin North Am 1992, 6:323–346.

8. Gallo GR, Feiner HD, Chuba JV, Beneck D, Marion P, Cohen DH: Characterization of tissue amyloid by immunofluorescence microscopy. Clin Immunol Immunopathol 1986, 39:479–490.

9. Randal RE, Williamson WC, Mullinax F, Tung MY, Still WJ: Manifestations of systemic light chain deposition. The Am J Me 1976, 60:293–299.

10. Preud’homme JL, Aucouturier P, Touchard G, Khamlichi AA, Rocca A, Denoroy L, Cogné M: Monoclonal immunoglobulin deposition disease: a review of immunoglobulin chain alterations. Int J Immunopharm 1994, 16:425–431.

11. Rostagno A, Frizzer G, Ylagan L, Kumar A, Ghiso J, Gallo G: Tumoral non-amyloidotic monoclonal immunoglobulin light chain deposits (‘aggregoma’): presenting feature of B-cell dyscrasia in 3 cases with immunohistochemical and biochemical analyses. Br J Haematol 2002, 119:62–69.

12. Tabatabai G, Baehring J, Hochberg FH: Primary amyloidoma of the brain parenchyma. Arch Neurol 2005, 62:477–480.

13. Gandhi D, Wee R, Goyal M: CT and MR imaging of intracerebral amyloidoma: case report and review of the literature. AJNR Am J Neuroradiol 2003, 24:519–522.

14. Fischer B, Palkovic S, Rickert C, Weckesser M, Wassmann H: Cerebral AL lambda-amyloidoma: clinical and pathomorphological characteristics. Review of the literature and of a patient. Amyloid 2007, 14:11–19.

15. Schröder R, Deckert M, Linke RP: Novel isolated cerebral AL lambda amyloid angiopathy with widespread subcortical distribution and leukoencephalopathy due to atypical monoclonal plasma cell proliferation, and terminal systemic gammopathy. J Neuropathol Exp Neurol 2009, 68:286–299.

16. Foreid H, Barros C, Evangelista T, Campos A, Pimentel J: Intracerebral amyloidoma: case report and review of the literature. Clin Neuropathol 2010, 29:217–222.

17. Pantazi G, Psaras T, Kocpe K, von Coellin R, Fend F, Bock T, Schittenhelm J, Melms A, Meyermann R, Bormann A: Cerebral low-grade lymphoma and light chain deposition disease: exceedingly high IgG levels in the cerebrospinal fluid as a diagnostic clue. Clin Neuropathol 2010, 29:378–383.

18. Fischer L, Korfel A, Stoltenburg-Didinger G, Ransco C, Thiel E: A 19-year-old male with generalized seizures, unconsciousness and a deviation of gaze. Brain pathol (Zurich, Switzerland) 2006, 16:185–187.

19. Popović M, Tavčar R, Glavac D, Volavek M, Pintosek Z, Vizjak A: Light chain deposition disease restricted to the brain: The first case report. Hum Pathol 2007, 38:179–184.

20. Schröder R, Linke RP: Cerebrovascular involvement in systemic AA and AL amyloidosis: a clear haematogenic pattern. Virchows Arch 1999, 434:551–560.

21. Laeng RH, Altermatt HJ, Schethauer BW, Zimmermann DR: Amyloidomas of the nervous system: a monoclonal B-cell disorder with monotypic amyloid light chain lambda amyloid production. Cancer 1998, 82:362–374.

22. van Garamen II, Lokhorst H, Hazenberg BPC, Vellenga E: Therapeutic options in systemic AL amyloidosis. The Neth J Med 2004, 62:106–113.

23. Paccalet M, Hachulla E, Gazeté C, Tircot L, Carreiro M, Rubi M, Grateau G, Roblot P: Localized amyloidosis: a survey of 35 French cases. Amyloid 2005, 12:239–245.